CTLA4 and pancreatic adenocarcinoma: Unlike most solid tumors, the activity of programmed cell death 1 receptor (PD-1)/programmed cell death ligand 1 (PD-L1)- and cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-blocking agents against PAAD is disappointing.